53901-95-4

Basic information

• Product Name: p-acetoxycinnamoyl chloride
• CAS NO: 53901-95-4
• Molecular Weight: 224.644
• Mol File: 53901-95-4.mol
• Article Data: 43

Chemical Properties

• CAS DataBase Reference: p-acetoxycinnamoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: p-acetoxycinnamoyl chloride(53901-95-4)
• EPA Substance Registry System: p-acetoxycinnamoyl chloride(53901-95-4)

Safety Data

• Hazardous Substances Data: 53901-95-4(Hazardous Substances Data)

Upstream product

• 27542-85-4 4-acetoxycinnamic acid 
• 878-00-2 4-formylphenyl acetate 
• 7400-08-0 p-Coumaric Acid 
• 108-24-7 acetic anhydride 
• 7400-08-0 para-coumaric acid 
• 123-08-0 4-hydroxy-benzaldehyde 
• 27542-85-4 3-(4-acetoxyphenyl)acrylic acid 

Downstream Products

• 58505-83-2 4‐((E)-2-formylvinyl)phenyl acetate 
• 86223-79-2 1-(4-Acetoxyphenyl)-7-methoxy-hepta-1,6-dien-4-in-3-on 
• 364048-98-6 tris[2(4-O-acetylcoumaroyl)aminoethyl]amine 
• 364049-01-4 N¹,N⁴,N⁷,N¹⁰,N¹³-penta(4-o-acetylcoumaroyl)tetraethylenepentamine 
• 364048-99-7 N¹,N⁶-di(4-O-acetylcoumaroyl)putrescine 
• 556065-57-7 4-[(1E)-3-({8-[(tert-butoxycarbonyl)amino]octyl}amino)-3-oxoprop-1-enyl]phenyl acetate 
• 556065-77-1 acetic acid 4-(2-{3-[4-(3-tert-butoxycarbonylamino-propyl)-piperazin-1-yl]-propylcarbamoyl}-vinyl)-phenyl ester 
• 556065-63-5 4-[(1E)-16,16-dimethyl-3,14-dioxo-7,10,15-trioxa-4,13-diazaheptadec-1-en-1-yl]phenyl acetate 
• 556065-59-9 4-[(1E)-3-({12-[(tert-butoxycarbonyl)amino]dodecyl}amino)-3-oxoprop-1-enyl]phenyl acetate 
• 556065-69-1 acetic acid 4-{2-[2-(2-tert-butoxycarbonylamino-ethylamino)-ethylcarbamoyl]-vinyl}-phenyl ester 
• 660426-60-8 Acetic acid 4-{(E)-2-[{2-[(E)-3-(4-acetoxy-phenyl)-acryloylamino]-ethyl}-(2-tert-butoxycarbonylamino-ethyl)-carbamoyl]-vinyl}-phenyl ester 
• 556065-67-9 4-[(1E)-20,20-dimethyl-3,18-dioxo-8,13,19-trioxa-4,17-diazahenicos-1-en-1-yl]phenyl acetate 
• 556824-25-0 acetic acid 4-(2-{3-[4-(3-tert-butoxycarbonylamino-propylamino)-cyclohexylamino]-propylcarbamoyl}-vinyl)-phenyl ester 
• 42933-21-1 octadecanyl-3-[4-hydroxyphenyl]-prop-2-enoate 

Relevant articles and documents

Development trans-N-benzyl hydroxyl cinnamamide based compounds from cinnamic acids and characteristics anticancer potency

The derivatization of three hydroxycinnamamides becomes trans-N-benzylhydroxycinnamamides, and their potential assay as anticancer agents has been carried out. N-benzyl-p-coumaramide (5a), N-benzylcaffeamide (5b), and N-benzylferulamide (5c) were obtained

Preparation method and application of hydroxyl cinnamyl ester type catechin

The invention relates to a preparation method and application of hydroxyl cinnamyl ester type catechins. The hydroxyl cinnamyl ester type catechins comprise four catechins which are respectively namedas epicatechin trans-coumarate, epicatechin trans-caffeic acid ester, epigallocatechin trans-coumarate and epigallocatechin trans-caffeic acid ester. The hydroxyl cinnamyl ester type catechins are prepared by the following steps: carrying out four steps of full acetylation on epicatechin and epigallocatechin, removal of acetyl on phenolic hydroxyl, silanizing of phenolic hydroxyl and removal of 3-acetyl, then respectively esterifying with acetylated caffeic acid or coumaric acid acyl chloride, and removing a protecting group. The preparation method of the four catechins is simple and mild inconditions, and can be completed under general experimental conditions. The four hydroxycinnamyl ester type catechins have a certain inhibition effect on the activity of alpha-glucosidase, can be usedfor hypoglycemic drugs, and have important significance in the fields of agriculture and medicine.

Synthesis of a series of benzothiazole amide derivatives and their biological evaluation as potent hemostatic agents

A series of benzothiazole amide derivatives were synthesized through a facile and efficient method via a nucleophilic acyl substitution reaction between 2-aminobenzothiazole and various cinnamic acid compounds. The obtained products exhibited good thermal stabilities. All compounds were evaluated for their in vitro hemostatic activities using the commercially available standard drug etamsylate as a positive control. The results showed that compound Q2 had a significant partial coagulation activity, reduced capillary permeability at 5, 10 and 50 μmol L-1, activated thrombin activity, and a more potent platelet aggregation activity than the positive control group (etamsylate, up to 1283.9 times in the nanomole range). A molecular modeling study revealed that compound Q2 was a competitive thrombin activator. Therefore, Q2 may be a potential lead for further biological screening and for the generation of drug molecules. Moreover, the structure-activity relationship of the prepared compounds is also discussed herein.